STOCK WATCH

LABSKIN, the Integumenowned company which makes clones of human skin for cosmetic testing, has announced it is rolling out its testing platform into the medical device and clinical research sectors.

The healthcare firm, which also analyses test results, said Labskin reduces the number of human volunteers required for a trial by 50pc.

It will also dramatically lower the costs of clinical trials, Integumen said.

Shares in Integumen jumped 16.3pc, or 0.27p, to 1.89p.